Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma

Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma

Immune checkpoint blockade of programmed cell death protein 1 (PD-1) had an impressive long-lasting effect in a portion of advanced-stage melanoma patients, however, this therapy failed to induce responses in several patients; how to increase the objective response rate is very important. Cellular F...

Full description

Bibliographic Details
Main Authors:	Yao Wang, Jing-jing Li, Hong-jun Ba, Ke-feng Wang, Xi-zhi Wen, Dan-dan Li, Xiao-feng Zhu, Xiao-shi Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-09-01
Series:	Frontiers in Oncology
Subjects:	c-FLIPL PD-1 PD-L1 B16 melanoma immune therapy
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.00857/full

Similar Items

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma
by: Yuchen Wang, et al.
Published: (2021-06-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma
by: Saeed Daneshmandi, et al.
Published: (2019-03-01)

Data analysis of PD-1 antibody in the treatment of melanoma patients
by: Ting Li, et al.
Published: (2020-06-01)

Response to PD‐1 blockade in a patient with mucosal melanoma of the middle ear: Case report
by: Hiroki Komatsuda, et al.
Published: (2020-12-01)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
by: Youhai Jiang, et al.
Published: (2020-03-01)

PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
by: Sandra Lassalle, et al.
Published: (2020-11-01)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
by: Sagun Parakh, et al.
Published: (2021-06-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
by: Marine Cordonnier, et al.
Published: (2020-01-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
by: Jiyun Lee, et al.
Published: (2019-08-01)

Correlation of MET and PD-L1 Expression in Malignant Melanoma
by: Kyu Young Song, et al.
Published: (2020-07-01)

Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
by: Xuanyi Wang, et al.
Published: (2020-04-01)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020-08-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
by: Paolo A. Ascierto, et al.
Published: (2019-03-01)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
by: Chen Q, et al.
Published: (2018-08-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
by: Ye Liu, et al.
Published: (2021-06-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity
by: Kathleen M. Kokolus, et al.
Published: (2019-02-01)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
by: Tian Tian, et al.
Published: (2021-09-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
by: Chen CY, et al.
Published: (2018-07-01)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
by: Umang Swami, et al.
Published: (2020-10-01)

PD-1 Blockade on Tumor Microenvironment-Resident ILC2s Promotes TNF-α Production and Restricts Progression of Metastatic Melanoma
by: Emily Howard, et al.
Published: (2021-08-01)

Metformin induces apoptotic cytotoxicity depending on AMPK/PKA/GSK-3β-mediated c-FLIPL degradation in non-small cell lung cancer
by: Luo Z, et al.
Published: (2019-01-01)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
by: Robainas M, et al.
Published: (2017-03-01)

Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
by: Lili Huang, et al.
Published: (2021-04-01)

Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes
by: L Marotte, et al.
Published: (2021-01-01)

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
by: Xiaoliang Liu, et al.
Published: (2019-08-01)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
by: Angel Garcia-Diaz, et al.
Published: (2017-05-01)

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
by: Gabriele Madonna, et al.
Published: (2018-12-01)

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways
by: Jing Li, et al.
Published: (2021-06-01)

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
by: Lu Xu, et al.
Published: (2018-10-01)

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
by: Masaki Terabe, et al.
Published: (2017-05-01)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
by: Li Zhou, et al.
Published: (2021-07-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)